Jordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, Kosj Yamoah, Alex C Soupir, Jonathan V Nguyen, Carlos Moran Segura, Adam M Spivak, Beatrice S Knudsen, Qin Zhou, Siwen Hu-Lieskovan, Sonam Puri, Wei Zhang, Yoko S DeRose, Gita Suneja, Anna E Coghill
{"title":"人类免疫缺陷病毒在肺癌、乳腺癌和前列腺癌肿瘤免疫微环境中的相关差异","authors":"Jordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, Kosj Yamoah, Alex C Soupir, Jonathan V Nguyen, Carlos Moran Segura, Adam M Spivak, Beatrice S Knudsen, Qin Zhou, Siwen Hu-Lieskovan, Sonam Puri, Wei Zhang, Yoko S DeRose, Gita Suneja, Anna E Coghill","doi":"10.1158/1055-9965.EPI-24-1421","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer outcomes in people living with HIV (PWH) may be driven in part by a distinct tumor microenvironment (TME) for tumors that develop in the setting of persistent immune dysfunction.</p><p><strong>Methods: </strong>Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without HIV.</p><p><strong>Results: </strong>A total of 292 samples were analyzed, 51 from PWH (lung cancer=17; breast cancer=14; prostate cancer=20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer (OR 1.88; 95% CI: 1.02-3.45), while CD11b+ cells were observed less frequently (OR 0.4; 95% CI: 0.17-0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PDL-1 (OR 3.24; 95% CI: 1.52-6.91), CD14 (OR 3.37; 95% CI: 1.14-10.0), and FOXP3 (OR 1.91; 95% CI: 1.03-3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PDL-1 (OR 5.94; 95% CI: 3.77-9.34); while 3 three markers had lower abundance including CD14 (OR 0.40; 95% CI: 0.22-0.74), as well as CD16 and CD11c.</p><p><strong>Conclusions: </strong>This pilot study showed that differences in the tumor immune microenvironment (TME) exist for PWH diagnosed with age-related NADCs compared to non-infected controls. Future work evaluating TME differences with related clinical endpoints is needed.</p><p><strong>Impact: </strong>Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.\",\"authors\":\"Jordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, Kosj Yamoah, Alex C Soupir, Jonathan V Nguyen, Carlos Moran Segura, Adam M Spivak, Beatrice S Knudsen, Qin Zhou, Siwen Hu-Lieskovan, Sonam Puri, Wei Zhang, Yoko S DeRose, Gita Suneja, Anna E Coghill\",\"doi\":\"10.1158/1055-9965.EPI-24-1421\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cancer outcomes in people living with HIV (PWH) may be driven in part by a distinct tumor microenvironment (TME) for tumors that develop in the setting of persistent immune dysfunction.</p><p><strong>Methods: </strong>Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without HIV.</p><p><strong>Results: </strong>A total of 292 samples were analyzed, 51 from PWH (lung cancer=17; breast cancer=14; prostate cancer=20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer (OR 1.88; 95% CI: 1.02-3.45), while CD11b+ cells were observed less frequently (OR 0.4; 95% CI: 0.17-0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PDL-1 (OR 3.24; 95% CI: 1.52-6.91), CD14 (OR 3.37; 95% CI: 1.14-10.0), and FOXP3 (OR 1.91; 95% CI: 1.03-3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PDL-1 (OR 5.94; 95% CI: 3.77-9.34); while 3 three markers had lower abundance including CD14 (OR 0.40; 95% CI: 0.22-0.74), as well as CD16 and CD11c.</p><p><strong>Conclusions: </strong>This pilot study showed that differences in the tumor immune microenvironment (TME) exist for PWH diagnosed with age-related NADCs compared to non-infected controls. Future work evaluating TME differences with related clinical endpoints is needed.</p><p><strong>Impact: </strong>Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.</p>\",\"PeriodicalId\":9458,\"journal\":{\"name\":\"Cancer Epidemiology Biomarkers & Prevention\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Epidemiology Biomarkers & Prevention\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1055-9965.EPI-24-1421\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-1421","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.
Background: Cancer outcomes in people living with HIV (PWH) may be driven in part by a distinct tumor microenvironment (TME) for tumors that develop in the setting of persistent immune dysfunction.
Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without HIV.
Results: A total of 292 samples were analyzed, 51 from PWH (lung cancer=17; breast cancer=14; prostate cancer=20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer (OR 1.88; 95% CI: 1.02-3.45), while CD11b+ cells were observed less frequently (OR 0.4; 95% CI: 0.17-0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PDL-1 (OR 3.24; 95% CI: 1.52-6.91), CD14 (OR 3.37; 95% CI: 1.14-10.0), and FOXP3 (OR 1.91; 95% CI: 1.03-3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PDL-1 (OR 5.94; 95% CI: 3.77-9.34); while 3 three markers had lower abundance including CD14 (OR 0.40; 95% CI: 0.22-0.74), as well as CD16 and CD11c.
Conclusions: This pilot study showed that differences in the tumor immune microenvironment (TME) exist for PWH diagnosed with age-related NADCs compared to non-infected controls. Future work evaluating TME differences with related clinical endpoints is needed.
Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
期刊介绍：
Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
